Valuation: KYORIN Pharmaceutical Co., Ltd.

Market Cap 60.43B 382M 341M 319M 289M 545M 36.96B 549M 3.83B 1.5B 18.8B 1.43B 1.4B P/E 2027 *
39x
P/E 2028 * 37.3x
Enterprise Value 60.43B 382M 341M 319M 289M 545M 36.96B 549M 3.83B 1.5B 18.8B 1.43B 1.4B EV / Sales 2027 *
0.49x
EV / Sales 2028 * 0.58x
Free-Float
60.02%
Yield 2027 *
2.38%
Yield 2028 * 2.38%
10-01 Daito, Meiji Seika Pharma, DBJ to Form JV to Take Over Kyorin Pharmaceutical's Generic Drug Business MT
08-03 KYORIN Pharmaceutical Co., Ltd. Commences Promotion Activities For Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5% CI
07-13 KYORIN Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd. Enter Joint Marketing Agreement for Allergic Conjunctivitis Treatment Alesion Cream 0.5% CI
05-12 KYORIN Pharmaceutical Co., Ltd. Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2027 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Announces Directorate and Executive Changes, Effective June 19, 2026 CI
05-12 KYORIN Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 4, 2026 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2027 CI
04-27 Japanese Stocks Climb as Iran's Plan to Reopen Strait Boosts Sentiment MT
04-26 Kyorin Pharma Signs MOU to Transfer Generic Drug Business to Daito Group MT
04-24 Daito Pharmaceutical Co Ltd Signs MOU with Kyorin Pharmaceutical Co Ltd to Transfer Generic Drug Business to New Joint Venture CI
04-23 Daito Pharmaceutical Co.,Ltd., Development Bank of Japan Inc. and Meiji Seika Pharma Co., Ltd signed a Memorandum of Understanding to acquire KYORIN Rimedio Co., Ltd from KYORIN Pharmaceutical Co., Ltd.. CI
03-31 Kyorin Pharmaceutical Co Ltd - Kyorin enters into license agreement with Biodol for novel neuropathic pain treatment RE
03-25 Kyorin Pharmaceutical Co., Ltd. and Johnson & Johnson Enter Exclusive Distribution and Promotion Agreement for Sirturo CI
1 day-0.47%
1 week-4.80%
Current month-4.80%
1 month-5.05%
3 months-11.67%
6 months-38.52%
Current year-31.55%
1 week 1,046
Extreme 1046
1,104
1 month 1,046
Extreme 1046
1,149
Current year 1,046
Extreme 1046
1,725
1 year 1,046
Extreme 1046
1,725
3 years 1,046
Extreme 1046
1,880
5 years 1,046
Extreme 1046
1,924
10 years 1,046
Extreme 1046
2,829
Manager TitleAgeSince
Chief Executive Officer 59 2023-03-31
Director of Finance/CFO 56 2023-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2011-05-31
Director/Board Member 78 2013-05-31
Director/Board Member 66 2015-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-4.80%-28.44%-42.55% 384M
+2.70%+0.35%+40.67%+110.31% 1,032B
+1.44%-3.41%+37.36%+63.95% 614B
+1.75%+3.07%+17.89%+83.05% 471B
+0.60%-4.35%+60.80%+37.46% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.49%+40.45%+54.44% 218B
+1.82%-2.93%+29.29%+96.48% 179B
Average +1.56%-3.51%+23.16%+49.62% 371.52B
Weighted average by Cap. +1.95%-3.18%+32.15%+70.58%

Financials

2027 *2028 *
Net sales 125B 788M 704M 657M 597M 1.12B 76.21B 1.13B 7.89B 3.08B 38.76B 2.96B 2.89B 104B 659M 589M 549M 499M 940M 63.73B 947M 6.6B 2.58B 32.41B 2.47B 2.42B
Net income 1.55B 9.8M 8.76M 8.17M 7.42M 13.98M 948M 14.08M 98.18M 38.36M 482M 36.79M 36M 1.62B 10.24M 9.15M 8.54M 7.76M 14.61M 991M 14.72M 103M 40.09M 504M 38.45M 37.62M
Net Debt - -
Projected Income Statement - Annual - KYORIN Pharmaceutical Co., Ltd.
Logo KYORIN Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Employees
1,982
Date Price Change Volume
26-10-07 JP¥1,052.00 -0.47% 203,600
26-10-06 JP¥1,057.00 +0.19% 132,300
26-10-05 JP¥1,055.00 -0.94% 204,800
26-10-02 JP¥1,065.00 -3.01% 289,600
26-10-01 JP¥1,098.00 -0.63% 164,300
Trader
-
Investor
Global
-
Quality
ESG MSCI
BB
Ratings Surperformance© - KYORIN Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1,052.00JPY
Average target price
1,100.00JPY
Spread / Average Target
+4.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - KYORIN Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4569 Stock